Prasinezumab is under clinical development by Prothena Corp and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Prasinezumab’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 17 Oct 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Prasinezumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Prasinezumab overview

Prasinezumab is under development for the treatment of Parkinson’s disease (PD) and other synucleinopathies. It is administered through intravenous route as an infusion. The drug candidate is a monoclonal antibody targeting alpha-synuclein. It is a new molecular entity (NME).

Prothena Corp overview

Prothena Corp (Prothena) discovers and develops therapies for the treatment of neurological disorders. It is evaluating Prasinezumab (PRX002/RG7935), a monoclonal antibody targeting alpha-synuclein protein, against Parkinson’s disease and other related synucleinopathies; and PRX004, an investigational antibody to treat transthyretin amyloidosis (ATTR amyloidosis), by targeting and clearing the misfolded (toxic) forms of the TTR amyloid protein. The company is also advancing its pipeline to treat Alzheimer’s disease (AD), frontotemporal dementia and amyotrophic lateral sclerosis (ALS). Prothena works in collaboration with Roche Holding AG, Bristol Myers Squibb and other companies to develop its products. It has operations in California, the United States. Prothena is headquartered in Dublin, Ireland.

Quick View Prasinezumab LOA Data

Report Segments
  • Innovator
Drug Name
  • Prasinezumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.